[Pharmacokinetics and clinical studies on cefsulodin in neonates]. 1989

S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
Department of Pediatrics, School of Medicine, Keio University.

Pharmacokinetics and clinical studies on cefsulodin (CFS) were conducted in neonates. 1. MIC's of CFS, sulbenicillin and gentamicin (GM) were determined using 7 strains of Pseudomonas aeruginosa clinically isolated from neonates and maintained as stock cultures. CFS was found to be nearly as active as GM. 2. When CFS 20 mg/kg was administered to a 12-day-old neonate by intravenous bolus injection, serum concentrations were 8.7 micrograms/ml before administration and 51.7 micrograms/ml at 30 minutes, 44.4 micrograms/ml at 1 hour, 38.6 micrograms/ml at 2 hours and 11.1 micrograms/ml at 6 hours after administration. The half-life was 2.5 hours. 3. CFS was administered alone or combination with other drugs to 3 neonates. The drug was clinically effective in 2 cases and slightly effective in another. Bacteriologically, one case was rated as decreased, another as replaced, and the remaining one as unchanged. 4. Neither side effects nor abnormal laboratory values attributable to CFS were found.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D010033 Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE. Middle Ear Inflammation,Inflammation, Middle Ear
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D002441 Cefsulodin A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients. Abbott 46811,CGP-7174-E,Cefsulodin Monosodium Salt,Cefsulodin Sodium,Monaspor,Pyocefal,SCE-129,CGP 7174 E,CGP7174E,Monosodium Salt, Cefsulodin,SCE 129,SCE129,Sodium, Cefsulodin
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
March 1990, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
December 1989, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
October 1981, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
November 1982, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
December 1989, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
November 1982, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
November 1982, The Japanese journal of antibiotics,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
January 1982, Archives of oto-rhino-laryngology,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
January 1982, Transactions - American Society for Artificial Internal Organs,
S Iwata, and Y Sato, and M Tojo, and Y Kusumoto, and H Shiro, and H Akita, and S Nanri, and T Oikawa, and M Osano, and S Kusano
December 1982, The Japanese journal of antibiotics,
Copied contents to your clipboard!